P3 Health Partners (NASDAQ:PIII) Announces Quarterly Earnings Results

P3 Health Partners (NASDAQ:PIII) posted its earnings results on Thursday. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.85) by $5.17, FiscalAI reports. P3 Health Partners had a negative net margin of 8.57% and a negative return on equity of 302.33%. The business had revenue of $386.39 million for the quarter, compared to analysts’ expectations of $391.45 million.

Here are the key takeaways from P3 Health Partners’ conference call:

• P3 reported $26 million of adjusted EBITDA in Q1, well above internal expectations, and raised its full-year 2026 outlook to $20 million-$60 million as execution improved.
• The company said its Medicare Advantage medical cost trend was roughly flat versus the full-year 2025 baseline, which it framed as a meaningful differentiator versus peers guiding to 7%+ trend.
• Management highlighted stronger payer economics, including about a 15% year-over-year improvement in MA funding rates and delegated functions covering 63% of membership in 2026.
• The company said its balance sheet improved after roughly $250 million of debt was converted to preferred equity, and it believes it now exceeds the Nasdaq minimum stockholders’ equity requirement.
• Membership declined year over year to about 106,000 at-risk lives as P3 exited lower-economics arrangements, but total lives under management reached about 135,000 including service arrangements and a new Nebraska partnership.

P3 Health Partners Price Performance

P3 Health Partners stock traded up $7.26 during trading hours on Friday, reaching $11.29. The stock had a trading volume of 65,159,971 shares, compared to its average volume of 134,546. The stock has a market cap of $81.43 million, a PE ratio of -0.29 and a beta of 0.48. P3 Health Partners has a 52 week low of $1.52 and a 52 week high of $14.35. The company has a fifty day simple moving average of $3.05 and a 200-day simple moving average of $3.85.

P3 Health Partners News Roundup

Here are the key news stories impacting P3 Health Partners this week:

• Positive Sentiment: P3 Health Partners reported Q1 2026 earnings of $0.32 per share, beating expectations for a large loss, which appears to be the main catalyst behind the stock’s surge. P3 Health Partners (PIII) Stock Surges Over 42% After Hours: Here’s Why
• Positive Sentiment: The company’s revenue for the quarter was $386.39 million, roughly in line with estimates, helping support investor confidence that operating results were better than expected overall. P3 Health Partners earnings press release
• Neutral Sentiment: Trading in PIII was halted several times for LULD pauses, indicating extreme volatility and a fast-moving price reaction to the earnings news.
• Neutral Sentiment: Commentary following the report highlighted that the stock was reacting to a narrower-than-expected loss and a sharp after-hours move, underscoring speculation and momentum trading rather than a fresh business announcement. P3 Health Partners (PIII) stock surges over 42% after hours: Here’s why
• Negative Sentiment: Despite the earnings beat, P3 Health Partners still reported a negative net margin and negative return on equity, so the underlying turnaround story remains unproven.

Wall Street Analyst Weigh In

PIII has been the topic of several research reports. TD Cowen lowered their price objective on shares of P3 Health Partners from $8.00 to $3.00 and set a “hold” rating on the stock in a research report on Thursday, April 2nd. Lake Street Capital restated a “buy” rating and set a $14.00 price objective (up from $4.00) on shares of P3 Health Partners in a research report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of P3 Health Partners in a research report on Tuesday, April 21st. Finally, UBS Group set a $14.00 target price on shares of P3 Health Partners in a report on Friday. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.33.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.